EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A Highly Potent, Orally Bioavailable Pyrazole-Derived Cannabinoid CB2 Receptor- Selective Full Agonist for In Vivo Studies

Andrea Chicca, Daniel Bátora, Christoph Ullmer, Antonello Caruso iD, Sabine Grüner, Jürgen Fingerle, Thomas Hartung, Roland Degen, Matthias Müller, Uwe Grether iD, Pal Pacher, Jürg Gertsch iD

ACS Pharmacology & Translational Science · 09.08.2024 · 7 (8) · 2424-2438

DOI: 10.1021/acsptsci.4c00269 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ACS Pharmacology & Translational Science, online erschienen am 09.07.2024. Verfasst von Andrea Chicca und 11 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Biochemistry and Molecular Medicine, University of Bern, Bern 3012, Switzerland. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Schweizerischer Nationalfonds zur F?rderung der Wissenschaftlichen Forschung, National Institute on Alcohol Abuse and Alcoholism.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Autor:innen und Institutionen

  • Institute of Biochemistry and Molecular Medicine, University of Bern, Bern 3012, Switzerland.
  • Graduate School for Cellular and Biomedical Sciences, University of Bern, Bern 3012, Switzerland.
  • Pharmaceutical Sciences, Roche Innovation Center Basel, Roche Pharma Research and Early Development, Basel 4070, Switzerland.
  • Laboratory of Cardiovascular Physiology and Tissue Injury (P.P.), National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health (NIH), Bethesda MD 20892-9304, United States.

ORCID-Profile: Antonello Caruso, Uwe Grether, Jürg Gertsch

Förderung

  • Schweizerischer Nationalfonds zur F?rderung der Wissenschaftlichen Forschung
  • National Institute on Alcohol Abuse and Alcoholism

Zitieren

APA

Chicca, A., Bátora, D., Ullmer, C., Caruso, A., Grüner, S., Fingerle, J., Hartung, T., Degen, R., Müller, M., Grether, U., Pacher, P., & Gertsch, J. (2024). A Highly Potent, Orally Bioavailable Pyrazole-Derived Cannabinoid CB2 Receptor- Selective Full Agonist for In Vivo Studies. ACS Pharmacology & Translational Science, 7(8), 2424-2438. https://doi.org/10.1021/acsptsci.4c00269

Vancouver

Chicca A, Bátora D, Ullmer C, Caruso A, Grüner S, Fingerle J, et al. A Highly Potent, Orally Bioavailable Pyrazole-Derived Cannabinoid CB2 Receptor- Selective Full Agonist for In Vivo Studies. ACS Pharmacology & Translational Science. 2024;7(8):2424-2438. doi:10.1021/acsptsci.4c00269

BibTeX
@article{Chicca2024,
  author = {Chicca, Andrea and Bátora, Daniel and Ullmer, Christoph and Caruso, Antonello and Grüner, Sabine and Fingerle, Jürgen and Hartung, Thomas and Degen, Roland and Müller, Matthias and Grether, Uwe and Pacher, Pal and Gertsch, Jürg},
  title = {A Highly Potent, Orally Bioavailable Pyrazole-Derived Cannabinoid CB2 Receptor- Selective Full Agonist for In Vivo Studies},
  journal = {ACS Pharmacology & Translational Science},
  year = {2024},
  volume = {7},
  number = {8},
  pages = {2424--2438},
  doi = {10.1021/acsptsci.4c00269}
}
Kostenlos starten →